Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes
- PMID: 16860974
- DOI: 10.1016/j.schres.2006.06.002
Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes
Abstract
Background: The goal of these secondary analyses of clinical trial data was to characterize clinical outcomes in patients with schizophrenia who met symptom severity or duration thresholds for two alternative definitions of remission, and to explore their relationships to improvement duration and quality of life outcomes.
Methods: Definition 1 used threshold criteria for selected PANSS items sustained over at least 6-months Definition 2 used Brief Psychiatric Rating Scale (BPRS) % change, a threshold score for the Clinical Global Improvement-Severity (CGI-S) maintained for at least 8 weeks, and threshold scores for selected BPRS items. Positive and Negative Symptom Scale (PANSS) and Quality of Life scale (QLS) total scores were pooled from 6 clinical trials. The extent to which the alternative severity thresholds from these two definitions and duration of clinical improvement were associated with different clinical and QLS outcomes was explored. Regression analysis also assessed the relative contribution of each of the components of the two definition severity thresholds to improvements in QLS Total score.
Results: Increases in QLS scores were greater for those patients who met either threshold criteria relative to those who met neither (p<.0001). Significantly greater improvements in QLS scores were observed for patients who met either threshold criteria at the 8-, 16- and 24-week visits relative to those who met criteria at weeks 16 and 24, or at week 24 only (p<0.001), as well as for the subset of patients who met threshold criteria at both 24 and 52 weeks relative to those who met criteria at only one of these 2 time points. Only 31% to 47% of patients meeting threshold criteria for either definition at the 8-, 16- or 24-week visits remained in remission at the 52-week visit. Among the severity threshold components analyzed, BPRS total % change from baseline was the strongest predictor of improvement in QLS scores.
Conclusions: Quality of life improved most for patients who achieved severity thresholds associated with either remission criteria and who stayed improved for longer periods. Total BPRS change scores accounted for the greatest percentage of the QLS scores variance. Only a fraction of patients who meet severity criteria for either remission definition early in treatment will remain at that level of improvement within the subsequent 9-12 months.
Similar articles
-
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?J Clin Psychiatry. 1999;60 Suppl 5:23-9; discussion 30. J Clin Psychiatry. 1999. PMID: 10192404 Review.
-
A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.Int Clin Psychopharmacol. 2014 Sep;29(5):279-87. doi: 10.1097/YIC.0000000000000030. Int Clin Psychopharmacol. 2014. PMID: 24583566 Clinical Trial.
-
Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.Int J Neuropsychopharmacol. 2009 Oct;12(9):1233-48. doi: 10.1017/S1461145709000352. Epub 2009 May 7. Int J Neuropsychopharmacol. 2009. PMID: 19419595 Clinical Trial.
-
Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.Schizophr Res. 2011 Mar;126(1-3):174-83. doi: 10.1016/j.schres.2010.10.024. Epub 2010 Dec 24. Schizophr Res. 2011. PMID: 21185155
-
Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia.Br J Psychiatry. 2011 Oct;199(4):275-80. doi: 10.1192/bjp.bp.110.083907. Br J Psychiatry. 2011. PMID: 22187729 Review.
Cited by
-
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial.Eur Arch Psychiatry Clin Neurosci. 2015 Mar;265(2):107-16. doi: 10.1007/s00406-014-0528-2. Epub 2014 Sep 27. Eur Arch Psychiatry Clin Neurosci. 2015. PMID: 25261210
-
Proposed criteria for schizophrenia remission.Neuropsychiatr Dis Treat. 2014 Apr 16;10:619-23. doi: 10.2147/NDT.S62744. eCollection 2014. Neuropsychiatr Dis Treat. 2014. PMID: 24790443 Free PMC article. No abstract available.
-
Shared and distinct alterations of white matter tracts in remitted and nonremitted patients with schizophrenia.Hum Brain Mapp. 2018 May;39(5):2007-2019. doi: 10.1002/hbm.23982. Epub 2018 Jan 28. Hum Brain Mapp. 2018. PMID: 29377322 Free PMC article.
-
Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).Ther Adv Psychopharmacol. 2013 Aug;3(4):191-9. doi: 10.1177/2045125313479127. Ther Adv Psychopharmacol. 2013. PMID: 24167692 Free PMC article.
-
Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.BMC Psychiatry. 2012 Dec 5;12:222. doi: 10.1186/1471-244X-12-222. BMC Psychiatry. 2012. PMID: 23216976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous